近日,在减肥药市场竞争不断加剧的背景下,诺和诺德传来一连串利好消息,公司股价因此出现大涨。
上周,诺和诺德在上海进博会上展出了其旗舰减肥药物司美格鲁肽的口服和注射版本,吸引了全球目光。与此同时,该公司还宣布与Ascendis Pharma达成合作,开发针对代谢疾病(包括肥胖和2型糖尿病)的长效GLP-1受体激动剂。这再次彰显了该公司在减肥药领域的布局实力。
而在11月6日,诺和诺德发布了2024年第三季度业绩。数据显示,公司第三季度净收入273亿丹麦克朗,超过市场预期。得益于减肥产品线的强劲表现,诺和诺德股价在盘后持续走高,目前涨超5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.